Spyre Therapeutics, Inc. (NASDAQ: SYRE) shares were down slightly Monday. The Waltham, Mass.-based concern, a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease and other immune-mediated diseases, today announced that the first patient has been dosed in its Phase 2 SKYWAY basket trial evaluating SPY072 in RA, PsA, and axSpA.
SPY072 is an extended half-life investigational antibody targeting TL1A, a cytokine central to T-cell-driven inflammation. Designed for superior potency, convenience, and durability, SPY072 may set a new standard in the treatment of rheumatic diseases with its potential for quarterly or twice-yearly subcutaneous maintenance dosing.
“RA, PsA, and axSpA collectively affect millions of patients globally, including more than three million in the U.S., yet the vast majority do not achieve durable remission with today’s therapies and require frequent injections or infusions,” said Josh Friedman, SVP of Clinical Development at Spyre.
The SKYWAY Phase 2 trial is a randomized and placebo-controlled study evaluating SPY072 in patients with moderately to severely active RA, PsA, or axSpA with inadequate response to conventional or advanced therapies. Topline 12-week (RA) and 16-week (PsA, axSpA) proof-of-concept data are expected in 2026.
SPRE shares began Monday gave back four cents to $15.61.
Related Stories
